Research Division, Institute of Mental Health, Singapore, Singapore.
Psychiatry Res. 2010 Jun 30;178(1):33-8. doi: 10.1016/j.psychres.2010.03.020. Epub 2010 May 6.
Growing interest in cognitive deficits associated with schizophrenia has led to the need for a clinician-friendly cognitive instrument. The Schizophrenia Cognition Rating Scale (SCoRS), recognized for its brevity and ease of administration, has proven to be a valid and reliable measure of overall cognition in schizophrenia patients. However, there has been no such validation in an Asian context. This SCoRS validation study involved 103 patient and 48 control subjects within an Asian population. Test-retest reliability, sensitivity of the instrument to cognitive differences between patients with schizophrenia and healthy controls as well as validity by comparing with a standardised performance-based cognitive battery, the Brief Assessment of Cognition in Schizophrenia (BACS) were assessed. Our findings indicated that SCoRS is highly reliable (ICC=0.984) and sensitive to cognitive dysfunction. SCoRS is significantly correlated with BACS composite scores and predicted functional outcomes as measured by Global Assessment of Functioning (GAF) and World Health Organisation-Quality of Life (WHO QOL) within an Asian population. SCoRS represents a clinician-friendly cognitive assessment tool that incorporates third-party feedback and might be employed in clinical practice to better evaluate and manage schizophrenia.
对与精神分裂症相关的认知缺陷的日益关注，导致需要一种适合临床医生使用的认知工具。精神分裂症认知评定量表（SCoRS）以其简洁和易于管理而著称，已被证明是一种评估精神分裂症患者整体认知的有效且可靠的测量工具。然而，在亚洲背景下，尚未对其进行验证。这项 SCoRS 验证研究涉及亚洲人群中的 103 名患者和 48 名对照受试者。在评估测试-重测信度、该工具对精神分裂症患者和健康对照者之间认知差异的敏感性以及与基于标准的表现认知成套测验（Brief Assessment of Cognition in Schizophrenia，BACS）的效标关联效度时，我们发现 SCoRS 具有高度可靠性（ICC=0.984），且对认知功能障碍敏感。SCoRS 与 BACS 综合评分显著相关，并能预测亚洲人群中整体功能评估（Global Assessment of Functioning，GAF）和世界卫生组织生活质量（World Health Organisation-Quality of Life，WHO QOL）的功能结果。SCoRS 代表了一种适合临床医生使用的认知评估工具，它整合了第三方反馈，可能会在临床实践中用于更好地评估和管理精神分裂症。
